Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Unknown 1Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Genitourinary 18Thoracic 4Dermatologic 4Gastrointestinal 3Other solid neoplasm 1Head & Neck 1Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 86Lung Neoplasms 32Small Cell Lung Carcinoma 18Melanoma 17Mesothelioma 13Neoplasms 11Colorectal Neoplasms 9Carcinoma, Renal Cell 9Squamous Cell Carcinoma of Head and Neck 7Neoplasm Metastasis 7Mesothelioma, Malignant 7Carcinoma, Transitional Cell 7Ovarian Neoplasms 6Diabetes Mellitus, Insulin-Dependent, 12 6Urinary Bladder Neoplasms 5Triple Negative Breast Neoplasms 5Pancreatic Neoplasms 5Liver Neoplasms 5Endometrial Neoplasms 5Carcinoma, Hepatocellular 5Uterine Cervical Neoplasms 4Stomach Neoplasms 4Kidney Neoplasms 4Brain Neoplasms 4Carcinoma, Merkel Cell 3Skin Neoplasms 2Sarcoma 2Prostatic Neoplasms 2Lung Diseases 2Head and Neck Neoplasms 2

Interventions

pembrolizumab 15Nivolumab 9atezolizumab 5Ipilimumab 4Drug Therapy 4Docetaxel 4Radiotherapy 3Radiosurgery 3Paclitaxel 3Gemcitabine 3Cetuximab 3Carboplatin 3Blood Specimen Collection 3temsirolimus 2spartalizumab 2sargramostim 2motexafin gadolinium 2liposomal doxorubicin 2entinostat 2durvalumab 2belinostat 2Sirolimus 2Psychiatric Rehabilitation 2Peripheral Blood Stem Cell Transplantation 2Metformin 2Irinotecan 2Fluorouracil 2Etoposide 2Dexamethasone 2Cyclophosphamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Kidney Neoplasms × Ipilimumab × Thoracic × Clear all
NCT06362369 2026-04-13

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

7 Hills Pharma, LLC

Phase 1/2 Recruiting
126 enrolled
DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Turcot syndrome, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Melanoma, Neoplasm Metastasis, Skin Neoplasms, Colorectal Neoplasms

NCT03693014 2025-10-06

A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
69 enrolled
GenitourinaryThoracic

Urinary Bladder Neoplasms, Kidney Neoplasms, Lung Neoplasms, Neoplasm Metastasis

NCT04311710 2023-02-24

CheckMate 76U

Bristol-Myers Squibb

Phase 1 Terminated
21 enrolled
DermatologicGastrointestinalGenitourinaryThoracic

Urinary Bladder Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Skin Neoplasms

NCT04107168 2023-02-16

Microbiome Immunotherapy Toxicity and Response Evaluation

Cambridge University Hospitals NHS Foundation Trust

Unknown
1,800 enrolled
DermatologicGenitourinaryThoracic

Kidney Neoplasms, Lung Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡